Skip to main content

Advertisement

Figure 1 | BMC Neurology

Figure 1

From: Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hocanalyses of the EPOC trial

Figure 1

Change in Treatment Satisfaction Questionnaire for Medication Global Satisfaction scores. The figure shows the LSM change from baseline to 6 months ± standard error. GA, glatiramer acetate; IFN, interferon; iDMT, injectable disease-modifying therapy; IM, intramuscular; LSM, least-squares mean; SC, subcutaneous.

Back to article page